Navigation Links
Protect Pharma Sells Patent Portfolio to Grunenthal GmbH
Date:2/9/2011

PRINCETON, N.J., Feb. 9, 2011 /PRNewswire/ -- Protect Pharmaceutical Corporation (OTC Bulletin Board: PRTT) announced today that it has completed the sale of two patents and patents-applications to Grunenthal GmbH, a German specialty pharmaceutical company that is a pioneer in pain drug discovery and research. The patent portfolio includes innovative pain drugs that address the large and underserved pain market.

Ram Sesha, Protect's Chief Operating Officer, said, "We are very happy to see Protect's programs are innovative and promising enough to attract someone like Grunenthal, a leader in pain drug discovery and research."

Protect still retains the patents related to abuse deterrent and once daily gastro-retentive drug delivery platforms and the corresponding three other ongoing projects. In the near term, Protect intends to proceed with a comprehensive program to develop and commercialize once-daily drugs for diabetic neuropathic pain, fibromyalgia, postherpetic neuralgia and epilepsy. Protect also plans to develop and commercialize once-daily opioid combinations as well as abuse-deterrent opioid combinations for moderate to severe pain.

About Protect Pharmaceuticals Corporation.

Based in Princeton, New Jersey, Protect (OTC Bulletin Board: PRTT) is a publicly held drug delivery and new product development company. Protect applies its proprietary drug delivery technologies to develop clinically effective drugs and is building a robust pipeline of product candidates based on its proprietary technologies, scientific knowledge and clinical expertise. For more information, visit www.protectpharm.com.

Safe Harbor Statement

This news release may contain certain forward-looking statements and information concerning Protect's business, operations, financial condition and prospects.  These statements are subject to various risks and uncertainties.  Actual results could differ materially from those currently anticipated due to a number of factors.  The information set forth herein should be read in light of such risks and uncertainties.  The Company assumes no duty or obligation to update these statements at any future date.


'/>"/>
SOURCE Protect Pharmaceutical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CeNeRx Announces FDA IND Approval for its Neuroprotective Agent in Chemotherapy-Induced Neuropathy and Results From First Human Study
2. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
3. Good Clostridia in the Gut Protect from Allergy and Autoimmunity
4. Published Study Concludes: Vented Baby Bottles Protect Essential Nutrients in Breast Milk and Formula
5. PROTECT II Interim Results Demonstrate That Impella Is Not Superior to the Intra-Aortic Balloon Pump in Reducing Major Adverse Events in High Risk Patients Receiving Percutaneous Coronary Interventions
6. Reportlinker Adds Neuroprotection - Drugs, Markets and Companies
7. NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010
8. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
9. Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project (QTDP) Grant Under the U.S. Patient Protection and Affordable Care Act of 2010
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. Mid*Lands IRB, LLC - First Independent IRB in Kansas and the Kansas City Area Awarded Accreditation for Protecting Research Participants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
Breaking Medicine News(10 mins):